Legend Biotech (LEGN) Stock Price
Legend Biotech Price
Revenue has compounded at 60.3% per year over the past 8 years to 1.03 B USD. Legend Biotech's net margin stands at -28.8%, up from -586.4% several years earlier. Analysts set a median price target of 59.00 USD, implying 174.7% above the current price. Of 22 analysts, 16 rate the stock a buy — an overall Buy consensus.
Legend Biotech stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Legend Biotech business model & stock analysis
Frequently asked questions about Legend Biotech
Legend Biotech Corp is a leading biopharmaceutical company that specializes in the discovery and development of innovative cell therapies. The company's business model revolves around leveraging its cutting-edge technologies and expertise in genetic engineering to develop personalized and off-the-shelf cell therapies for the treatment of various forms of cancer. By harnessing the power of the immune system, Legend Biotech aims to revolutionize the field of oncology and improve patient outcomes. With a focus on research and development, collaborations, and strategic partnerships, Legend Biotech is dedicated to advancing the future of cell-based immunotherapy and transforming the way cancer is treated.
Legend Biotech Corp is primarily active in the field of biotechnology.
The main competitors of Legend Biotech Corp in the market include prominent biotechnology companies such as Gilead Sciences, Inc., Celgene Corporation, and bluebird bio, Inc.
Legend Biotech Corp is a renowned biopharmaceutical company that focuses on developing cutting-edge cell therapies for patients with cancer. Founded in 2015 and headquartered in Somerset, New Jersey, Legend Biotech Corp is an affiliate of Genscript Biotech Corporation. The company primarily specializes in CAR-T cell therapies and has established a strong global presence. With a strong emphasis on research and development, Legend Biotech Corp has collaborated with numerous academic institutions and industry experts to advance the field of cell therapy. Leveraging its expertise and innovative approach, the company strives to improve the lives of patients worldwide by providing novel and effective treatments for various types of cancer.
Legend Biotech Corp has achieved several significant milestones in its trajectory. Notably, the company successfully completed a Phase 1b/2 clinical trial for its lead product candidate, LCAR-B38M CAR-T cell therapy. This innovative therapy demonstrated compelling clinical responses in patients with relapsed or refractory multiple myeloma, leading to breakthrough status designation by the U.S. FDA. Subsequently, Legend Biotech Corp went on to initiate a global Phase 2 pivotal trial for LCAR-B38M. These achievements showcase the company's dedication to advancing groundbreaking treatments for patients, solidifying its position as a frontrunner in the biotech industry.
Legend Biotech Corp is primarily present in multiple countries and regions. With its headquarters in Somerset, New Jersey, the company has an extensive global presence. It operates in key markets such as the United States, China, and Europe. Legend Biotech Corp has established strategic collaborations and partnerships to extend its reach and leverage market opportunities. By expanding its operations internationally, the company aims to capitalize on the diverse healthcare landscapes and maximize its potential for growth and innovation.
Legend Biotech Corp is a leading biopharmaceutical company that values innovation, integrity, and a patient-centric approach. With a strong corporate philosophy focused on advancing novel cell therapies, Legend Biotech Corp strives to improve the lives of patients around the world. The company is committed to developing cutting-edge treatments for oncology and autoimmune diseases, utilizing its expertise in gene and cell therapies. With a dedication to scientific excellence and a patient-first mindset, Legend Biotech Corp continues to push the boundaries of medical innovation and deliver transformative therapies to those in need.
Analysts currently set an average price target of 57.22 USD for the Legend Biotech stock (median: 59.00 USD), implying +166.4 % versus the latest price. The consensus is based on 22 analyst ratings.
22 analysts currently rate the Legend Biotech stock: 16 recommend buying, 6 holding and 0 selling. For 2026, analysts expect Legend Biotech to generate revenue of 1.44 B USD and earnings per share of -0.09 USD.
Converted at the current exchange rate, the Legend Biotech share trades at 19.12 EUR (21.48 USD).
The Legend Biotech share (LEGN) is listed on 4 stock exchanges, including: NASDAQ (LEGN), Frankfurt (9LB.F), München (9LB.MU), Düsseldorf (9LB.DU).
Legend Biotech Corp is an innovative biotechnology company specializing in the development of cell therapies for cancer and autoimmune diseases. The company was founded in 2015 and is headquartered in Somerset, New Jersey. Its business model focuses on discovering and developing therapies for difficult-to-treat diseases, utilizing expertise in gene and cell therapy as well as a proprietary platform for designing, manufacturing, and optimizing therapy products. The company has two main divisions: cancer therapy and autoimmune therapy. In cancer therapy, Legend Biotech Corp focuses on developing immunotherapies that activate the body's immune system to destroy cancer cells, with a promising pipeline of cell therapies for various types of cancer. In autoimmune therapy, the company is developing cell therapies for diseases such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus, using a similar approach to the cancer therapy division. The company's product portfolio includes several products in various stages of clinical development, including CAR-T cell therapies for the treatment of Hodgkin's lymphoma and multiple myeloma. Legend Biotech Corp also places a strong emphasis on partnerships and collaborations, working closely with research institutions, universities, and other biotechnology companies to optimize its technology and therapy platforms and develop new products. Overall, the company's business model is characterized by innovative research and development, a focus on discovering new therapies, and close collaboration with partners and other industry stakeholders. The company is well positioned to develop and bring successful cell therapies for cancer and autoimmune diseases to the market.
The expected revenue of Legend Biotech is 1.44 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Legend Biotech is -15.90 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Legend Biotech is currently -249.61. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Legend Biotech stock.
The price-to-sales ratio (P/S) of Legend Biotech is currently 2.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Legend Biotech stock.
The Eulerpool Quality Score for Legend Biotech is 3/10.
The ISIN of Legend Biotech is US52490G1022. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Legend Biotech is A2P5AH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Legend Biotech is LEGN. The ticker symbol is used to trade Legend Biotech shares on the stock exchange.
Legend Biotech stock
Legend Biotech Peer Group
Legend Biotech Ticker
Legend Biotech FIGI
All fundamentals and in-depth analysis of Legend Biotech
Our stock analysis for Legend Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Legend Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.